precision medicine

Research in Review

New Treatment Effective for B-Cell Precursor ALL in Pediatric Patients

11/17/2016

JCP Editors

Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to a study published in the Journal of...

...

11/17/2016

Journal of Clinical Pathways

Interview

ACS CAN Addresses Controversy Surrounding Opioids

11/15/2016

Mark Fleury, PhD, MS

An interview with Mark Fleury, PhD, MS, principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network, Washington, DC.  Pain as a result of cancer or cancer treatment...

An...

11/15/2016

Journal of Clinical Pathways

Research in Review

Significant Cost Savings From Enhanced Recovery Pathway for Colorectal Surgery

11/15/2016

JCP Editors

A new study has shown that an Enhanced Recovery After Surgery (ERAS) pathway for colorectal surgery can help to reduce complications from health services utilization and significantly reduce total...

A new...

11/15/2016

Journal of Clinical Pathways

Research in Review

Study Examines Cost-Effectiveness of Treatment Sequencing for HER2-Positive Breast Cancer

11/15/2016

JCP Editors

Targeted therapies have been shown to significantly improve the survival of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer. However, these therapies have also been associated...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

Pembrolizumab Better Than Chemotherapy for Urothelial Cancer

11/14/2016

JCP Editors

An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...

An...

11/14/2016

Journal of Clinical Pathways

Quiz

Best Targeted Therapy for Melanoma

11/10/2016

JCP Editors

A study published in JAMA Oncology recently showed that treatment with which of the following drug types was just as effective as BRAF- and MEK-targeted therapies for melanoma and also limited the risk of...

A...

11/10/2016

Journal of Clinical Pathways

Research in Review

TKI Shows Promise in Sarcoma Study

11/10/2016

JCP Editors

Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according...

...

11/10/2016

Journal of Clinical Pathways

Research in Review

Glioblastoma Characteristics Provide Evidence for Prognosis, Treatment of Older Patients

11/09/2016

JCP Editors

According to researchers, characteristics of glioblastoma including seizures, location, and pressure in the brain give valuable insight into length of survival as well as treatment options for patients over the age...

...

11/09/2016

Journal of Clinical Pathways

Research in Review

High Potential for Drug-Drug Interactions With New Antineoplastic Agents

11/03/2016

JCP Editors

Most oral antineoplastic drugs approved in the past six years are associated with multiple, clinically significant drug-drug interactions (DDIs). Therefore, the onus remains on oncologists to be more of aware DDIs...

Most...

11/03/2016

Journal of Clinical Pathways

Neutrophil-to-Lymphocyte Ratio Not a Prognostic or Predictive Marker for Bladder Cancer

10/31/2016

JCP Editors

The neutrophil-to-lymphocyte ratio (NLR) may not be as reliable as previously believed at predicating cancer progression and which drugs will be the most effective, according to results published in Cancer. Risk...

The...

10/31/2016

Journal of Clinical Pathways